# A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

> **NCT04232878** · PHASE1 · TERMINATED · sponsor: **Cerevel Therapeutics, LLC** · enrollment: 10 (actual)

## Conditions studied

- Substance Use Disorders (SUD)

## Interventions

- **DRUG:** CVL-936
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT04232878
- **Lead sponsor:** Cerevel Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-16
- **Primary completion:** 2020-03-06
- **Final completion:** 2020-05-21
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sufficient data has been obtained to meet current objectives
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04232878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04232878, "A Single Ascending Dose Trial of CVL-936 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04232878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*